Get in touch.
Stay connected.


message.png

Whether you have product-related questions or need Repatha® samples, Repatha® Sales Representatives are here to help you and your office staff.

First Name

Enter first name

Last Name

Enter last name

Email

Enter email address

Zip Code

Enter zip code

I am a...

Select your title

Phone Number

Enter Phone Number

To report an adverse event, please call 1-800-77-AMGEN (1-800-772-6436).

Privacy Statement
By clicking "Submit," you agree to disclose your personal information to Amgen and to be contacted by Amgen and their agents in the future regarding products, services, and/or information related to Repatha®. For more information about Amgen's privacy practices, please visit www.amgen.com/privacy.


Submit

Thank you.


Submit

RepathaReady®

Offers patient support services




For patient injection support, RepathaReady® nurses can help.


Nurse support is available in other languages, including Spanish.


Call 1-844-REPATHA (1-844-737-2842), available 7 days a week, 9 AM–11 PM ET.


For injection information, have patients visit www.RepathaInjection.com.




RepathaReady® also provides Educational emails and medication reminders


How to take Repatha® demo videos

Watch Video

Helpful resources and tools for providers and patients

View resources



For more information, call
1-844-REPATHA (1-844-737-2842)
7 days a week, 9 AM-11 PM ET.


Important Safety Information

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

Allergic Reactions: Hypersensitivity reactions (e.g. angioedema, rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse Reactions in Primary Hyperlipidemia (including HeFH): The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52‐week trial and seven 12‐week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®‐treated and placebo‐treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising.

Allergic reactions occurred in 5.1% and 4.7% of Repatha®‐treated and placebo‐treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Adverse Reactions in the Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and occurring more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new‐onset diabetes mellitus during the trial was 8.1% in patients assigned to Repatha® compared with 7.7% in those assigned to placebo.

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Please see full Prescribing Information.